AU2021368769A1 - Use of an anti-cd19 antibody to treat autoimmune disease - Google Patents

Use of an anti-cd19 antibody to treat autoimmune disease Download PDF

Info

Publication number
AU2021368769A1
AU2021368769A1 AU2021368769A AU2021368769A AU2021368769A1 AU 2021368769 A1 AU2021368769 A1 AU 2021368769A1 AU 2021368769 A AU2021368769 A AU 2021368769A AU 2021368769 A AU2021368769 A AU 2021368769A AU 2021368769 A1 AU2021368769 A1 AU 2021368769A1
Authority
AU
Australia
Prior art keywords
patient
nmosd
antibody
vib551
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021368769A
Other languages
English (en)
Other versions
AU2021368769A9 (en
Inventor
Eliezer Katz
John Ratchford
William Rees
Dewei SHE
Li Yan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viela Bio Inc
Original Assignee
Viela Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viela Bio Inc filed Critical Viela Bio Inc
Publication of AU2021368769A1 publication Critical patent/AU2021368769A1/en
Publication of AU2021368769A9 publication Critical patent/AU2021368769A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021368769A 2020-10-29 2021-10-29 Use of an anti-cd19 antibody to treat autoimmune disease Pending AU2021368769A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063107182P 2020-10-29 2020-10-29
US63/107,182 2020-10-29
US202163143541P 2021-01-29 2021-01-29
US63/143,541 2021-01-29
US202163178286P 2021-04-22 2021-04-22
US63/178,286 2021-04-22
PCT/US2021/057443 WO2022094334A1 (en) 2020-10-29 2021-10-29 Use of an anti-cd19 antibody to treat autoimmune disease

Publications (2)

Publication Number Publication Date
AU2021368769A1 true AU2021368769A1 (en) 2023-06-08
AU2021368769A9 AU2021368769A9 (en) 2024-05-30

Family

ID=81384348

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021368769A Pending AU2021368769A1 (en) 2020-10-29 2021-10-29 Use of an anti-cd19 antibody to treat autoimmune disease

Country Status (10)

Country Link
US (1) US20230287114A1 (https=)
EP (1) EP4237447A4 (https=)
JP (1) JP2023549075A (https=)
KR (1) KR20230097118A (https=)
AU (1) AU2021368769A1 (https=)
CA (1) CA3197022A1 (https=)
IL (1) IL302294A (https=)
MX (1) MX2023004794A (https=)
TW (1) TW202233676A (https=)
WO (1) WO2022094334A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023534916A (ja) * 2020-06-30 2023-08-15 ビエラ バイオ インコーポレイテッド 視神経脊髄炎スペクトラム障害を治療する方法
WO2025202213A1 (en) 2024-03-26 2025-10-02 Institut National de la Santé et de la Recherche Médicale Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201401465D0 (en) * 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
MX2021012870A (es) * 2019-04-24 2022-01-18 Viela Bio Inc Uso de un anticuerpo anti cúmulo de diferenciación 19 (cd19) para tratar enfermedades autoinmunitarias.
JP2023534916A (ja) * 2020-06-30 2023-08-15 ビエラ バイオ インコーポレイテッド 視神経脊髄炎スペクトラム障害を治療する方法

Also Published As

Publication number Publication date
EP4237447A1 (en) 2023-09-06
KR20230097118A (ko) 2023-06-30
IL302294A (en) 2023-06-01
EP4237447A4 (en) 2024-07-17
WO2022094334A1 (en) 2022-05-05
JP2023549075A (ja) 2023-11-22
TW202233676A (zh) 2022-09-01
AU2021368769A9 (en) 2024-05-30
MX2023004794A (es) 2023-09-15
CA3197022A1 (en) 2022-05-05
US20230287114A1 (en) 2023-09-14

Similar Documents

Publication Publication Date Title
Pittock et al. Hope for patients with neuromyelitis optica spectrum disorders—from mechanisms to trials
Prasad et al. What you need to know about AQP4, MOG, and NMOSD
US20230287114A1 (en) Use of an anti-cd19 antibody to treat autoimmune disease
WO2023140269A1 (en) Treatment of autoimmune encephalitis with satralizumab
Wingerchuk Neuromyelitis optica spectrum disorders
KR20240107372A (ko) 사트랄리주맙을 사용하는 중추 신경계(cns)의 탈수초화 질환의 치료
AU2020263418A1 (en) Use of an anti-CD19 antibody to treat autoimmune disease
Valencia-Sanchez et al. Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders: C. Valencia-Sanchez et al.
Correa-Díaz et al. Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders
EP4132564A1 (en) Ofatumumab for treating ms while maintaining serum igg
Kim et al. Monoclonal antibody therapies for multiple sclerosis and neuromyelitis optica spectrum disorder
Sharma et al. Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein IgG associated disorder: A comprehensive neuro‐ophthalmic review
JP2022501378A (ja) 視神経脊髄炎の処置のためのエクリズマブ
CN116322765A (zh) 用于用奥瑞珠单抗治疗多发性硬化症的方法
KR20230030642A (ko) 시신경척수염 스펙트럼 장애를 치료하는 방법
HK40096777A (zh) 使用抗cd19抗体治疗自身免疫性疾病
CA3217586A1 (en) Use of an anti-cd19 antibody to treat myasthenia gravis
Lorefice et al. Monoclonal antibodies: a target therapy for multiple sclerosis
Yamout et al. Consensus Recommendations for the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD): The MENACTRIMS Guidelines
CN116583538A (zh) 使用抗cd19抗体治疗自身免疫性疾病
Beyer et al. Neuromyelitis optica in a patient with an early onset demyelinating episode: clinical and autoantibody findings
Sharma et al. Highly Aggressive Relapsing Course of Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease Requiring Intensive Care Unit Treatment and Quadruple Immunotherapy
Pfeuffer et al. NMO spectrum disorders
EA052907B1 (ru) Применение антитела к cd19 для лечения миастении гравис
HK40107811A (zh) 使用萨特利珠单抗治疗中枢神经系统(cns)的脱髓鞘疾病

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ SHE, DEWEI; RATCHFORD, JOHN; KATZ, ELIEZER; REES, WILLIAM; XIN, YAN AND RAMPAL, NISHI

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ SHE, DEWEI; RATCHFORD, JOHN; KATZ, ELIEZER; REES, WILLIAM AND YAN, LI

SREP Specification republished